Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

mCRPC × talazoparib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 26 Triple Negative Breast Neoplasms 11 Prostatic Neoplasms 10 Ovarian Neoplasms 9 Neoplasms 9 Neoplasm Metastasis 7 Leukemia, Myeloid, Acute 5 Small Cell Lung Carcinoma 4 Fallopian Tube Neoplasms 4 Endometrial Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Solid Tumors 3 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma, Ewing 2 Recurrence 2 Pancreatic Neoplasms 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Carcinoma, Renal Cell 2 Carcinoma, Ovarian Epithelial 2 mCRPC 1 Wilms Tumor 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Thrombocythemia, Essential 1 Stomach Neoplasms 1 Solid Tumor 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1

Interventions

enzalutamide 2 tislelizumab 1 talazoparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡